Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

EU Panel Backs Venetoclax/Rituximab Combo in Relapsed/Refractory CLL

September 22nd 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use is supporting the approval of venetoclax in combination with rituximab for patients with chronic lymphocytic leukemia who have received at least 1 previous therapy.

CLL Paradigm Continues to Be Refined

September 20th 2018

Erlene Seymour, MD, discusses novel therapies as well as their potential applications in the treatment paradigm of chronic lymphocytic leukemia.

Dr. O'Brien Discusses Duvelisib in CLL

September 18th 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses the promise of duvelisib in the treatment landscape of chronic lymphocytic leukemia.

Dr. Pinilla-Ibarz on the Impact of Venetoclax in CLL

September 13th 2018

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the impact of venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

FDA Updates Venetoclax CLL Label With MRD Data

September 12th 2018

The FDA has added minimal residual disease data from the phase III MURANO trial to the label for venetoclax for its approved use in combination with rituximab for previously-treated patients with chronic lymphocytic leukemia.

Dr. Brander on the Treatment of Relapsed/Refractory CLL

September 8th 2018

Danielle Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Pinilla-Ibarz on the Role of Chemotherapy in CLL

September 7th 2018

Javier A. Pinilla-Ibarz, MD, PhD, senior member, Moffitt Cancer Center, discusses the role of chemotherapy in patients with chronic lymphocytic leukemia (CLL).

Dr. Dimopoulos Reflects on Ibrutinib Plus Rituximab in Waldenstrom Macroglobulinemia

August 27th 2018

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.

Dr. O'Brien Discusses Combination Venetoclax in CLL

August 22nd 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses combination venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia.

Dr. Brander Discusses the Frontline Treatment of CLL

August 14th 2018

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia.

O'Brien Shares Overview of CLL Sequencing

August 10th 2018

Susan M. O'Brien, MD, discusses some of the latest intriguing data in the treatment of chronic lymphocytic leukemia and what this means for physicians and patients.

Dr. Barrientos on Advances in the Treatment Landscape for Patients With CLL

August 8th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses advances in the treatment landscape for patients with chronic lymphocytic leukemia (CLL).

Dr. O'Brien on Sequencing Small Molecule Inhibitors in CLL

August 6th 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses sequencing small molecule inhibitors in chronic lymphocytic leukemia (CLL).

Rai Helped Launch an Age of Innovation in Leukemia

August 5th 2018

Kanti R. Rai, MD, has been a leader in the diagnosis and treatment of chronic lymphocytic leukemia for more than 40 years. He was honored in the Hematologic Malignancies category with a 2017 Giants of Cancer Care® award.

Talley Traces Developments in Chronic Leukemias

August 3rd 2018

Robert L. Talley, MD, elaborates on the clinical trial findings that are shifting standards of care in chronic leukemias.

Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

July 26th 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses reducing the risk of tumor lysis syndrome during the treatment of patients with chronic lymphocytic leukemia.

Expert Reviews Current State of CLL Treatment

July 24th 2018

Danielle Brander, MD, highlights how recent advances are changing the field of chronic lymphocytic leukemia and what it means for patients and their oncologists.

Umbralisib Shows Promise in Relapsed/Refractory CLL

July 23rd 2018

Anthony R. Mato, MD, MSCE, discusses the next steps for umbralisib and the biggest challenges still facing patients with chronic lymphocytic leukemia.

Dr. Brander on the Treatment Landscape for Patients With High-Risk CLL

July 20th 2018

Danielle Marie Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the treatment landscape for patients with high-risk chronic lymphocytic leukemia (CLL).

Expert Shares Insights on CLL Treatment Paradigm

July 20th 2018

Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.